FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

The Need for High-Purity A9 Dopaminergic Neurons Within Parkinson’s Disease Models

The Need for High-Purity A9 Dopaminergic Neurons Within Parkinson’s Disease Models

By | 22 October 2025

Understand the biological significance of A9 vs. A10 dopaminergic neuron subtypes in Parkinson’s disease
Learn how HD-DoE technology enables targeted development of A9 neurons with desired phenotypic profiles
Review of key phenotypic and functional QC benchmarks
Discussion of recommended use cases and applications in discovery and disease modeling